Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
Pennington P, Weinstock-Guttman B, Kolb C, Jakimovski D, Sacca K, Benedict RHB, Eckert S, Stecker M, Lizarraga A, Dwyer MG, Schumacher CB, Bergsland N, Picco P, Bernitsas E, Zabad R, Pardo G, Negroski D, Belkin M, Hojnacki D, Zivadinov R. Pennington P, et al. Among authors: kolb c. J Neurol. 2023 Feb;270(2):1095-1119. doi: 10.1007/s00415-022-11405-3. Epub 2022 Nov 14. J Neurol. 2023. PMID: 36376729
Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.
Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R. Kappus N, et al. Among authors: kolb c. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):181-7. doi: 10.1136/jnnp-2014-310051. Epub 2015 Feb 26. J Neurol Neurosurg Psychiatry. 2016. PMID: 25722366
Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study.
Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F. Zivadinov R, et al. Among authors: kolb c. Radiology. 2016 Dec;281(3):884-895. doi: 10.1148/radiol.2016160060. Epub 2016 Jun 16. Radiology. 2016. PMID: 27308776
Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. Gandhi S, et al. Among authors: kolb c. Expert Opin Biol Ther. 2016 Sep;16(9):1151-62. doi: 10.1080/14712598.2016.1213810. Epub 2016 Jul 27. Expert Opin Biol Ther. 2016. PMID: 27413840 Review.
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, Minagar A, Zivadinov R. Jakimovski D, et al. Among authors: kolb c. Expert Opin Biol Ther. 2017 Sep;17(9):1163-1172. doi: 10.1080/14712598.2017.1347632. Epub 2017 Jul 3. Expert Opin Biol Ther. 2017. PMID: 28658986 Review.
Interferon β for Multiple Sclerosis.
Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Jakimovski D, et al. Among authors: kolb c. Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003. Cold Spring Harb Perspect Med. 2018. PMID: 29311124 Free PMC article. Review.
Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B. Zivadinov R, et al. Among authors: kolb c. J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10. J Neurol Sci. 2018. PMID: 29571854
360 results